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ABSTRACT
Refractory ascites is a frequent complication of advanced
cirrhosis and is associated with hepatorenal syndrome
and hepatic hydrothorax. Large volume paracentesis and
pleurodesis are regarded as first-line treatments in
patients who do not respond adequately to diuretics.
These treatments, however, do not prevent recurrence
and carry the risk of worsening of the circulatory
dysfunction leading to hepatorenal syndrome. The
transjugular intrahepatic portosystemic shunt (TIPS) has
been proposed as an alternative to paracentesis. TIPS
reduces the rate of ascites recurrence mainly due to the
reduction in the filtration pressure. In addition, TIPS
results in a positive effect on renal function, including
hepatorenal syndrome, demonstrated by a rapid increase
in urinary sodium excretion, urinary volume, and
improvement in plasma creatinine concentration.
Furthermore, plasma renin activity, aldosterone, and
noradrenalin concentrations improve gradually after TIPS
insertion suggesting a positive effect on systemic
underfilling, the factor of hepatorenal syndrome. As
demonstrated recently in two meta-analyses including
five randomised studies, TIPS also improves survival
when compared with paracentesis. However, the
evidence is based on relatively few studies with only 305
patients included. The positive effects of the TIPS are
opposed by an increased frequency and severity of
episodes of hepatic encephalopathy which may be
reduced by both patient selection and reduced shunt
diameter. Based on the present knowledge the
recommended hierarchy of treatments for refractory
ascites may be reconsidered upgrading TIPS in suitable
candidates.
INTRODUCTION
Refractory ascites is defined by its unresponsiveness to
diuretics and characterised by oliguria and reduced
urinary sodium excretion. Refractory ascites is also
present in patients with tense ascites who do not
tolerate diuretic medication due to side effects such
as azotaemia, hyponatraemia, hyperkalaemia, or
hepatic encephalopathy.1 2 Recidivant ascites recurs
three times or more a year despite prescription of
diuretics in adequate dosage and recommendation of
sodium restriction.1 The occurrence of ascites indi-
cates poor prognosis with a 5-year survival of 50%. If
ascites becomes refractory to diuretics 50% of
patients die within 1 year.1e3
Hepatorenal syndrome (HRS) is a frequent andmost
serious complication of refractory ascites. Two types
are distinguished: a progressive, severe type 1, and
a type 2 which shows a more constant renal
dysfunction and is commonly associated with
refractory ascites.4 Hepatic hydrothorax is also
a consequence of ascites occurring in up to 10% of
these patients.5 The mostly right-sided, generally
large effusion is caused by transition of fluid from the
abdominal cavity into the pleural space due to a leak
in the diaphragm. Hepatic hydrothorax often results
in permanent hospitalisation and early death.
The treatment of refractory or recidivant and of
tense ascites and its associated complications has
changed considerably during recent years. Large
volume paracentesis (LVP)6 has been shown to be
safe, easy to perform, and has the advantages of
immediate relief of complaints and reduced duration
of hospitalisation.2 7 However, the negative effects of
LVP on systemic haemodynamics and renal function
often limit its use as a permanent treatment, in
particular in patients who are not candidates for liver
transplantation and who need life-long paracenteses.
For such patients, the transjugular intrahepatic
portosystemic shunt (TIPS) offers a treatment
option which does not exert negative effects on
systemic haemodynamics or renal function.
TIPS (figure 1) was introduced in 1988 as
a decompressive interventional treatment of portal
hypertension with the primary intention to treat
variceal bleeding.8 9 Nowadays, TIPS is mainly
being used for the treatment of ascites. Thus, as
shown by the German TIPS registry,10 in the past
4 years 68% of patients receiving a TIPS had
refractory ascites and only 32% were treated for
variceal bleeding.
PATHOPHYSIOLOGY OF ASCITES FORMATION AND
HRS
The hydrostatic pressure in portal hypertension is
composed of structural and dynamic components.
The structural changes in the cirrhotic liver lead to
an increase in its vascular resistance. This is further
enhanced by a dynamic and reversible constriction
of sinusoids by hepatic stellate cells.11 Another
dynamic mechanism of portal hypertension is
a defective regulation of the splanchnic arteriolae.12
It combines arterial underfilling with a forward
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increase in splanchnic capillary pressure and blood
flow with increased filtration and lymph formation.
The presently favoured hypothesis on the path-
ophysiology of cirrhotic ascites formation is the
forward-flow theory which is based on the
peripheral arterial vasodilatation hypothesis.12e14
Accordingly, sinusoidal hypertension initiates
a cascade of events leading to ascites formation, but
is itself not the dominant factor in its develop-
ment.15 Thus, sinusoidal hypertension induces
systemic vasodilatation and reduces systemic
vascular resistance, which is most evident in
splanchnic blood vessels. Splanchnic vasodilatation
leads to a forward increase in filtration across
splanchnic capillaries.16 The lymphatic system is
not capable of returning all the filtered fluid which
causes ascites formation. Furthermore, systemic
vasodilatation causes central vascular underfilling,
which stimulates sodium retaining neurohumoral
mechanisms. This triggers sodium retention, water
retention (with dilutional hyponatraemia) and
renal vasoconstriction, which may lead to hepa-
torenal syndrome.14 15
RATIONALE OF TREATMENTS FOR REFRACTORY
ASCITES, EFFECTS AND SIDE EFFECTS
Paracentesis
With ongoing disease severity acites becomes
intractable or refractory to the dietary and diuretic
therapy requiring additional measures. Large
volume paracentesis (LVP) relieves symptoms
rapidly and has few technical complications.7
However, it does not correct the underlying
problem leading to ascites formation and, therefore,
ascites reappears in almost all patients requiring
serial use of paracenteses.
LVP has haemodynamic side effects. Shortly after
LVP the cardiac output increases and the mean
arterial blood pressure decreases by 8e10 mmHg17 18
together with a further decline of the peripheral
and splanchnic vascular resistance.19 Consequently,
paracentesis may lead to a further increase in
splanchnic blood flow and portal pressure
causing an increased filtration rate and rapid ascites
re-accumulation.19 In addition, paracentesis aggra-
vates central vascular underfilling with a further
activation of the reninealdosterone and sympa-
thetic nervous systems leading to renal dysfunction
and eventually to the hepatorenal syndrome.20 21
This complication is termed as ‘postparacentesis
circulatory dysfunction’ which limits the use of
LVP in patients with unstable renal function. The
infusion of albumin during or shortly after the
paracentesis reduces the incidence of post-
paracentesis circulatory dysfunction from about
50% to 15%.21 22
TIPS
The rationale for TIPS is to decrease the portal
pressure and the filtration into the peritoneal space
to a level which can be drained by the lymphatic
system. Thus, in contrast to diuretics and para-
centesis, TIPS may counteract the mechanisms
leading to ascites formation.
Within 4 weeks after TIPS urinary sodium
excretion and serum creatinine improve signifi-
cantly and, in combination with diuretics, can
normalise within 6e12 months (figure 2).23e38 This
is associated with a gradual increase in urinary
volume and glomerular filtration rate.25 37 In addi-
tion, serum sodium concentration increases gradu-
ally.25 28 33 As shown in figure 3, the plasma
renin activity, aldosteron and noradrenalin
concentrations decreased significantly during 4e6
months of follow-up by 80%, 80% and 31%,
respectively.25 26 28 32 33 36 37 This indicates an
improvement of the circulatory dysfunction which
is demonstrated in figure 4. Opening of the shunt
leads to a sudden increase of the cardiac preload
with an increase of the central venous pressure by
100% from an average of 5.7e11.6 mm Hg.39 40
This is accompanied by a major increase of the
cardiac output from 7.8e11.5 l/min and a decrease
in the total systemic vascular resistance by 35%.39
After a few hours, the haemodynamic changes
return towards pre-TIPS conditions with a mild
persisting increase in the cardiac output by about 1
l/min and a decreased total vascular resistance by
about 20% for the following months.39e44 As
demonstrated in two studies with 12 months
follow-up37 40 cardiac output and peripheral
vascular resistance return to the pre-TIPS levels.
Figure 1 Schematic illustration of a transjugular intrahepatic portosystemic shunt (TIPS) and shunt angiography.
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The effect of TIPS on renal haemodynamics has
been investigated in six studies 28 29 32 33 37 45
showing normalisation after a follow-up of
12 months. Recently46 it was demonstrated that
TIPS results in an improved renal blood flow
together with an upward and leftward shift of the
renal blood flow/renal perfusion pressure relation-
ship curve which represents the renal autor-
egulation by the sympathetic nervous system.
Accordingly, a significant reduction in norepineph-
rine levels was observed. It was, however, not
normalised and was significantly higher than
normal and similar to that in patients with
diuretic-responsive ascites. The effect on the
norepinephrine concentration and renal blood flow
was directly related to the portosystemic pressure
gradient. These results support a previous study of
the same group showing that opening and occlu-
sion of the TIPS channel exerts a rapid effect on
renal blood flow.31 The authors concluded that the
findings support the existence of a previously
postulated hepato- or porto-renal reflex.47
With respect to the hepatic blood flow, TIPS
leads to a reduction in the portal perfusion of the
liver, dependent on the shunt diameter and the
degree of the portal pressure reduction. In most
patients a reduction of the portal pressure by about
50% results in a complete loss of the hepatic portal
blood flow seen at angiography. Accordingly, duplex
sonography after the TIPS commonly shows
retrograde flow direction or stagnant flow in the
intrahepatic portal branches indicating an abolished
portal perfusion of the liver. This is counter-
balanced by an immediate increase in the arterial
blood flow as demonstrated by Duplex sonog-
raphy48 and endoluminal flow measurements
during the TIPS procedure.49 The calculated average
arterial liver perfusion per minute increased from
5996100 ml/min before to 7496161 ml/min after
TIPS. The effect occurred within seconds after
opening the shunt and disappeared also within
seconds after its balloon occlusion.
With respect to other complications related to
portal hypertension a meta-analysis50 comparing
TIPS with paracentesis investigated three frequent
complications which occurred during the follow-
up: gastrointestinal bleeding, spontaneous bacterial
peritonitis (SBP) and HRS. Among patients allo-
cated to TIPS gastrointestinal bleeding occurred in
13 subjects (8%), SBP in three (2%), and HRS in
seven (4.6%), respectively. Among patients allo-
cated to paracentesis, gastrointestinal bleeding
occurred in 20 subjects (12.7%), SBP in five (3%),
and HRS in 20 (12.7%), respectively. The overall
rate of portal hypertension-related complications
was significantly lower in the TIPS group than in
the paracentesis group (23/149, 15% vs 45/156,
28%; p¼0.005).
TIPS may also have a positive effect on quality of
life. One study including 21 patients with refrac-
tory or recidivant ascites rated quality of life,
fatigue and physical performance on a scale (range
0e100) before and 3 and 6 months after TIPS
implantation.51 In addition, quality of life was
determined by the QoL index (range 0e10) intro-
duced by Spitzer. Patients’ ratings on the self-
assessment scale increased significantly from
35625 to 64628. Similarly, the Spitzer index
significantly improved from 6.962.0 to 8.362.1.
However, a randomised study on refractory ascites
did not show a difference of quality of life between
the TIPS and the paracentesis groups.52
Malnutrition and protein wasting is seen in most
patients with cirrhosis and refractory ascites and
Figure 2 Effects of a transjugular intrahepatic portosystemic shunt (TIPS) on urinary sodium excretion and creatinine
concentration. Data are extracted from 16 studies.23e38
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has a negative effect on survival.53 54 In contrast to
paracentesis, which leads to a protein loss of about
200 g per 10 litres ascites removed, TIPS improves
the protein metabolism and nutrition. Three
studies show a significant improvement in dry
weight, total body nitrogen, total body fat and
total body protein55e57 (figure 5). This is in agree-
ment with our findings of an increase in body
weight despite resolution of ascites.58 The reasons
for the positive effects of TIPS on nutrition are not
known. One reason may be an increase in the
systemic insulin concentration bypassing now the
liver. Another reason may lie in the disappearance
of the ascites which may lead to an improved
appetite and absorption of nutrients.
The drawbacks of TIPS are an increased incidence
of hepatic encephalopathy (HE) and the negative
effect on liver function. HE occurs in about 30% of
patients after TIPS.59 60 Factors associated with the
development of encephalopathy that can be used
for patient selection are advanced age, liver or renal
failure, and a history of encephalopathy before
TIPS insertion.61e63 Encephalopathy usually
becomes clinically apparent 2e3 weeks after TIPS
insertion and then declines (as measured by the
portosystemic encephalopathy index) at 6 months
in bare but not in covered stents.59 60 63 Thus,
shunt stenosis with time may reduce the incidence
of HE.
As demonstrated in a meta-analysis of individual
patient data50 the cumulative probability of devel-
oping a first episode of HE during follow-up was
not different between TIPS and paracentesis groups
(p¼0.36 by log-rank) and a similar result was found
for the development of severe HE (p¼0.46 by log-
rank). By contrast, when the average number of
episodes-per-patient was considered, patients allo-
cated to TIPS had significantly more episodes of HE
with regard to both, total number of episodes
(1.1361.93 vs 0.6361.18, p¼0.006) and number of
severe episodes (0.6861.0 vs 0.2460.50, p¼0.008).
Independent predictors of post-TIPS HE were
baseline mean arterial pressure (MAP) (HR 0.93, CI
0.89e0.98; p¼0.004), model of end stage liver
disease (MELD) score at baseline (HR 1.068, CI
1.006 to 1.13; p¼0.032), and post-TIPS porto-
systemic pressure gradient (HR 0.93, CI 0.87 to
0.99; p¼0.048). An explanation for the correlation
of baseline MAP with HE may be that a low MAP
reflects poor liver and brain perfusion together with
advanced disease. This is confirmed by the finding
that the increase in hepatic arterial blood flow after
TIPS has a potential predictive value of post-
procedural HE and mortality.64 With respect to the
MELD score, the INR and bilirubin concentration
reflect liver function and the creatinine concentra-
tion the haemodynamic impact of the liver disease
similar to the MAP. Theoretically, the combination
of bilirubin and MAP or the MELD score may both
be promising predictors for HE in patients with
cirrhosis with and without a TIPS. Unfortunately,
the study by Salerno50 does not provide thresholds
with lower or higher probabilities of HE after TIPS.
However, with a mean MAP of 87 mm Hg and
Figure 3 Effects of a transjugular intrahepatic portosystemic shunt (TIPS) on plasma renin activity, aldosterone and noradrenalin concentrations. Data
are obtained from eight studies.23 25 26 28 32 33 36 37
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a mean MELD score of 12.5 values of <80 mm Hg
or above 15 may be regarded as risk indicators for
HE.
The TIPS diameter, which can be adjusted during
the TIPS intervention, correlates inversely with the
portosystemic pressure gradient after TIPS, the
remaining portal liver perfusion and the liver
function. In patients at risk for HE according to the
parameters mentioned, a smaller shunt diameter
may be less harm and should therefore be preferred.
Treatment of HE is medical in most of the cases
and consists of controlling any precipitating factor,
lactulose and non-absorbable antibiotics (neomycin
or rifaximin).60 62 If medical therapy fails, the TIPS
diameter can be reduced or the shunt occluded.65e67
In this situation one should be assured that the
patient’s quality of life benefits more from
improving HE than it worsens by the re-accumu-
lation of ascites. Fortunately, in a series of 1000
patients, the need for shunt reduction for debili-
tating HE was only 3%.68
Deterioration of liver function after TIPS is
indicated by an increase of serum bilirubin
concentration.42 69 Its magnitude depends on the
baseline liver function. As demonstrated, a bilirubin
concentration of >3 mg/dl was closely correlated
with mortality (RR: 5.4, 95% CI: 1.4 to 10.2).70 The
finding is confirmed by showing that an elevated
pre-TIPS bilirubin is a powerful independent
predictor of 30-day mortality after TIPS creation
with a 40% increased risk of death for each 1 mg/dl
increase above 3.0 mg/dl.71 Therefore, a bilirubin
concentration above 3 mg/dl can be regarded as
a relative and above 5 mg/dl as an absolute
contraindication for TIPS implantation for refac-
tory ascites.72
To prevent both deterioration of liver function
and HE the shunt diameter and the degree of
reduction of the portosystemic pressure gradient
should be moderate. As demonstrated recently, 25
of 27 patients who developed hepatic encephalop-
athy after TIPS implantation had a pressure
gradient of <12 mm Hg.73 Thus, in patients with
a higher risk of HE and poor liver function (ie,
bilirubin concentration above 3 mg/dl) the porto-
systemic pressure gradient should be decreased
with great caution.
TECHNICAL ASPECTS OF TIPS
Complications
Although many serious complications have been
reported and summarised,74 no prospective study on
technical complications has been published so far.
The estimated technical success rate is reported in
the range of 93e100% and procedure-related
mortality is very low (<1%) andmainly due to intra-
abdominal bleeding.74 Technical complications
comprisemispuncture of the carotid artery (2%), the
hepatic artery and the bile ducts (6% each), and
rupture of the liver capsule (6%).10 Clinical conse-
quences of these technical complications are rare.
Many interventional radiologists consider TIPS
insertionmore difficult and possibly accompanied by
more complications in patients with refractory
ascites. This, however, is not our experience.10 To
avoid procedural problems, as much ascites as
possible should be removed before TIPS. This facili-
tates the access to a suitable hepatic vein and
improves the patient’s respiratory function.
Temporary cardiac complications such as
arrhythmia if the catheter enters the right atrium
or right ventricle are often seen but rarely serious.
In the presence of cirrhotic cardiomyopathy the
haemodynamic changes upon TIPS may lead to
manifest cardiac dysfunction seen in a few patients
after TIPS insertion.75 Therefore an ejection frac-
tion below 50% has been regarded as a relative and
below 40% as an absolute contraindication for
Figure 4 Effects of a transjugular intrahepatic portosystemic shunt (TIPS) on systemic hemodynamics. Data are
obtained from nine studies.39e45
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TIPS. Since the ejection fraction of patients with
cirrhosis is usually greater than 60%76 only few
patients will be precluded from TIPS. As shown
recently, cardiac diastolic dysfunction may also
play a role in a patient’s survival after TIPS.77 In
particular, a reduced E/A ratio predicted a poorer
survival after TIPS.
A complication which was encountered mainly
in the early 1990s is anaemia due to haemolysis. It
is probably due to mechanical damage of erythro-
cytes when passing with a high velocity of up to
2 m/s through the wire mesh of the stent.74 The
complication is now rare and limited possibly
because of improved stents. This is also true for the
stent migration into the right heart or lungs which
is almost abandoned by the use of self-expandable
nitinol stents.
As with any intravenous intervention, systemic
infection or septicaemia may not be avoided
completely. In the experience of the authors and
based on previous studies74 antibiotics are not
needed in general. They may, however, be indicated
after complicated and long-lasting procedures with
a great number of guide wire and catheter exchanges.
Shunt failure
Shunt insufficiency is frequent with bare stents and
occurs in 50e80% during 1 year of follow-up.74 In
many cases it may be due to bile duct involvement
which may lead to ‘endotipsitis’ followed by
intimal proliferation and thrombosis. It can be
prevented by introducing covered stents and
reduced by subcutaneous low molecular weight
heparin for 4 weeks possibly together with trapidil
and ticlopidin for 12 months.78 Our present prac-
tical approach in patients receiving bare stents is
the adapted application of up to 2000 U of heparin
intravenously during stent implantation followed
by low molecular weight heparin subcutaneously
during the index hospitalisation and a platelet
aggregation inhibitor (eg, acetyl salicylic acid
100 mg/day for at least 6 months) in patients with
platelet count >100 000/ml.
Shunt insufficiency does not necessarily indicate
the need for shunt revision. Shunt revision is indi-
cated in patients who fail initial response or who
have recurrence of ascites. With the availability of
stents covered with polytetrafluoroethylene
(Goretex), long-term patency rates of 80e90% have
been described.79 80
Shunt diameter, type of stent
The diameter of the shunt is crucial for effects and
side effects.50 73 The decision of the individual
shunt diameter ranging between 7 and 12 mm
needs consideration of all aspects of the liver disease
and the patient’s biomedical characteristics. It
should therefore be the result of a clinical judge-
ment before the intervention. As demonstrated in
patients with variceal bleeding,81 the reduction of
the pressure gradient must not always reach the
12 mm Hg threshold. The same is possibly true for
the treatment of ascites. As ascites formation
begins within a wide range of porto-systemic
pressure gradient ranging from about 12e40 mm
Hg (mean of 24 mm Hg),24 the therapeutic reduc-
tion to below 12 mm Hg which is almost always
efficient,73 is not always necessary.82 A smaller
reduction of the gradient by about 25e50% fits
better to the individual requirements and showed
promising results with a 1-year response rate of
93%.82 Thus, in most patients it may be advisable
to implant a 10 mm stent but dilate it to only
6e8 mm. In cases of insufficient response further
dilatation can be performed.
As for the shunt diameter, the choice of the stent
type is also a decision with clinical relevance which
should be discussed before the intervention. In
a patient with a higher risk of shunt-related
complications such as age over 60 years, bilirubin
around 3 mg/dl, presence of some degree of enceph-
alopathy or with a poor prognosis, uncovered stents
may be preferred because they allow spontaneous
narrowing in case of worsening of liver function or
HE. In contrast, patients with a low risk of compli-
cations or with BuddeChiari syndrome may have
a covered stent a priori to avoid unnecessary revi-
sions. A randomised study including patients with
varices and ascites found a better survival with the
covered stent graft.83 This may, however, not apply
to ascites patients who did not show a correlation
between shunt failure and survival.50 In patients
with BuddeChiari syndrome covered stents can
provide better results.84 85The effects and side effects
of the treatments are summarised in box 1.
TIPS VERSUS PARACENTESIS: SURVIVAL AND
EFFICACY
Survival
Five randomised studies from France,29 Germany,58
Spain/USA,86 USA/Canada,52 and Italy87 have been
published which showed poorer, similar or
improved survival with TIPS (table 1). Several
reasons could be identified to explain these varia-
tions including differences in technical skills,
patient selection and data analysis.
Table 2 summarises three technical quality
parameters of the TIPS procedure: success rate of
Figure 5 Effects of a transjugular intrahepatic portosystemic shunt (TIPS) on nutrition.56
Twenty-one patients were studied before and 6 months after TIPS. Body weight, muscle
mass, body cell mass, resting energy expenditure and energy intake increased
significantly while fat mass did not change significantly. In a subgroup of 16 patients
followed over a 12-month period the parameters further improved (not demonstrated).
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the TIPS intervention, reduction of the portosys-
temic pressure gradient and rate of secondary
patency. The first study published in 199629 differs
considerably with respect to technical success
(77%), reduction in pressure gradient (6 mm Hg),
and the rate of secondary TIPS patency (46%). As
demonstrated by D’Amico et al88 the technical
variables correspond to the ORs for mortality
suggesting that technical disability was the reason
for the poor outcome of TIPS in the French study.29
Therefore, the French study should be regarded as
an outlier. It should be borne in mind that this was
the first study, and therefore the experience with
TIPS was limited.
Second, selection of patients may have influenced
the results. About 40e60% of patients screened
were included in the trials with the exception of the
American study52 which included only 21% of the
source population.89 Selection also depends on
inclusion and exclusion criteria. It can be biased due
to unbalanced criteria favouring one of the two
treatment arms. Thus, the use of different inclusion
and exclusion thresholds for the bilirubin and
creatinine concentrations may be a source of bias
(table 3). Both parameters are equally important as
markers for liver or kidney function. Since the TIPS
may worsen liver function (but improve kidney
function) and the paracentesis worsens kidney
function (but has no effect on liver function) one
should request similar concentrations of bilirubin
and creatinine to provide equal chances for the
treatment arms and to avoid a selection bias. As
shown in table 3 all studies disfavoured the TIPS
groups by including patients with much higher
bilrubin than creatinine concentrations. The
Spanish study86 allowed inclusion of patients with
a bilirubin concentration as high as 10 mg/dl, which
is a clear contraindication for a portosystemic
shunt. On the other hand, in the American study52
inclusion and exclusion conditions selected patients
with an almost normal renal function but with
severe liver dysfunction, a fine condition for the
paracentesis arm but a clear disadvantage for the
TIPS arm.90
Third, survival analysis in all studies was
performed according to the method described by
Kaplan and Meier. However, studies differ in
providing transplant-free survival. This is of
particular importance when the time to trans-
plantation differs between the groups. In the two
studies providing the time to transplantation,52 87
TIPS patients had a much longer time to trans-
plantation than did paracentesis patients. Unfor-
tunately, the American study52 did not present
a transplant-free survival analysis although this
trial included the highest proportion of trans-
planted patients.
Four meta-analyses of these five studies88 91e93
have been published and are summarised in table 4.
Surprisingly, they show different results although
the calculations were done on an identical body of
data.
The first study91 lacks sophisticated statistical
evaluation and calculation of heterogeneity. The
second analysis92 provides relative risks which are
not identical to the commonly used ORs and thus
is difficult to compare. Considering survival,
heterogeneity between the studies was found but
authors made no effort to investigate and eliminate
its source. A meta-analysis by the Cochrane Insti-
tute93 is hampered by incorporating incorrect data
of the Italian publication.87 This is why their OR
for survival differs from the other meta-analyses.
The best meta-analysis was performed by
D’Amico.88 It identified the French study as the
source of heterogeneity of survival probabilities.
After eliminating this study as an outlier, hetero-
geneity disappeared. Actuarial rates of survival were
clearly different between groups favouring TIPS
(POR 0.74).
Finally, the inappropriate survival analysis in the
American study52 was overcome by Salerno et al50
who analysed individual patient data. Their find-
ings with respect to survival/mortality are
summarised in table 5. After excluding the French
study and analysing transplant-free survival, TIPS
patients were found to live significantly longer than
the patients treated with paracentesis. TIPS also
improved the estimated transplant-free survival in
patients with MELD scores between 10 and 20
suggesting that even patients with severe disease
may benefit from TIPS. In a multivariate analysis,
factors predicting mortality were older age (HR
0.61, 95% CI 0.41 to 0.91, p¼0.015), high bilirubin
Table 1 Two-year survival rates of randomised studies
comparing transjugular intrahepatic portosystemic shunt
(TIPS) and paracentesis
Author, year (Ref) n
2-year survival (%)
p ValueTIPS Paracentesis
Lebrec 199629 25 29 60 0.03
Ro¨ssle 200058 60 58 32 0.02
Gines 200286 70 26 30 0.51
Sanyal 200352 109 62 62 NS
Salerno 200487 66 79 29 0.021
Note the great differences within treatment arms with significantly
improved survival for the paracentesis group (Lebrec) or the TIPS group
(Ro¨ssle, Salerno).
Box 1
< Large volume paracentesis may deteriorate
hyperdynamic circulation and renal function in
particular when performed without adequate
substitution of albumin.
< TIPS corrects central vascular underfilling and
improves renal function, but has a higher
frequency of hepatic encephalopathy.
< Side effects depend on the diameter of the shunt
and on the reduction of the hepaticevenous
pressure gradient which should be adjusted
according to risk factors.
< Covered stents may offer improved patency and
yield better results in selected patients.
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levels (HR 1.22, 95% CI 1.029 to 1.048, p¼0.022),
low sodium concentration (HR 0.95, 95% CI 0.92
to 0.99, p¼0.03), and TIPS (HR 0.61, 95% CI 0.41
to 0.91, p¼0.015).
Treatment efficacy
A recent analysis of the literature on TIPS for
refractory ascites including 16 studies showed
a complete response in 51%, complete and partial
response not requiring paracenteses in 68% of the
patients.94 The five randomised studies discussed
before29 52 58 86 87 show a mean response to TIPS in
76% of patients. As shown in the meta-analysis by
Salerno50 recurrence of tense ascites occurred in
42% of patients allocated to TIPS and 89% of
patients allocated to paracentesis (p<0.0001).
Recurrence is mostly due to shunt insufficiency and
can be effectively treated by TIPS revision.
Accordingly, the average number of paracenteses-
per-patient was significantly lower in patients
allocated to TIPS (1.663.5 vs 7.168.8; p<0.0001)
whereas allocation to paracentesis resulted in an
independent association to recurrence of ascites
(OR 11.67, 95% CI 6.2 to 21.9).
TREATMENT OF HEPATORENAL SYNDROME
The definition of HRS was elaborated in 19961 and
updated in 2007.4 Accordingly, type 1 HRS is
a rapidly progressive disease defined by doubling of
initial serum creatinine concentrations to a level
greater than 226 mmol/l (2.5 mg/dl) in less than
2 weeks. HRS type 1 usually occurs within the
setting of an acute deterioration of circulatory
function characterised by arterial hypotension and
activation of endogenous vasoconstrictor systems.
Hospital mortality is as high as 90%. Type 2 HRS is
characterised by moderate renal failure with serum
creatinine concentrations between 1.5 mg/dl and
2.5 mg/dl with a steady or slowly progressive
course. It appears spontaneously, but can also
follow a precipitating event and is typically asso-
ciated with refractory ascites. Treatment of HRS
has changed in the recent years considerably.
Specific pharamological therapy includes plasma
expansion using albumin and vasoconstrictors such
as terlipressin.
Vasoconstrictor therapy
Terlipressin in combination with albumin is the
most widely studied pharmacological treatment for
patientswith type 1HRS. Complete response occurs
in approximately 40% of patients treated for
amaximumof 15 dayswith terlipressin and albumin
and is associated with improved survival.4 95
TIPS
Numerous studies in patients with refractory
ascites including the five randomised studies show
that TIPS improves renal function and haemody-
namic variables. Even patients with cirrhosis and
parenchymal kidney disease may benefit from
TIPS.35 Many patients with HRS type 1, however,
suffer from advanced hepatocellular insufficiency
with serum bilirubin exceeding 5 mg/dl, a clear
contraindication for TIPS. However, mortality after
liver transplantation is higher in patients trans-
planted with HRS than in those without
HRS.96This may argue in favour for TIPS in
transplantation candidates. A recent study
confirms this contention.97 It showed that TIPS
improves post-transplant graft and patient survival
significantly possibly due to an improved pre-
transplant renal function and portal blood supply
of the graft.
Only a few studies have assessed the role of
TIPS for the treatment of HRS in a total of 61
patients.33 36 38 98 Brensing et al36 treated 31 non-
transplantable patients (14 type 1 and 17 type 2)
and found that renal function improved following
TIPS. One- and 2-year survival rates were 20% for
type 1 and 70% and 45%, respectively, for type 2
HRS. However, due to a bilirubin cut-off of 10 mg/
dl, nine patients had to be excluded from TIPS.
Liver failure was one of the most frequent causes of
death following TIPS. Guevara et al33 reported on
seven patients with type 1 HRS showing a signifi-
cant improvement in serum creatinine, blood urea
nitrogen, glomerular filtration rate and renal
plasma flow by TIPS. Three patients survived by
more than 3 months. As shown by Wong et al98
TIPS may also have a role in maintaining patients
Table 3 Inclusion and exclusion threshold values for
bilirubin and creatinine concentrations
Author, year (Ref) Bilirubin (mg/dl) Creatinine (mg/dl)
Lebrec 199629 n.g. n.g.
Ro¨ssle 200058 <5 <3
Gines 200286 <10 <3
Sanyal 200352 <5 <1.5
Salerno 200487 <6 <3
n.g., not given.
Table 2 Variables assessing technical quality of the transjugular intrahepatic portosystemic shunt (TIPS)
intervention88
Author, year (Ref) Technical success (%)
Reduction in portosystemic pressure
gradient mm Hg (%) Secondary patency rate (%)
Lebrec 199629 77 6 (30) 46
Ro¨ssle 200058 100 14 (58) 93
Gines 200286 97 10.4 (54) 91
Sanyal 200352 94 11.5 (58) >90
Salerno 200487 89 13.8 (61) 82
The secondary patency rate is the patency achieved by shunt revision. The French study shows exceptional values.
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who initially respond to vasoconstrictor treatment.
Fourteen patients with type 1 HRS were treated
using a combination of midodrine, octreotide and
albumin. Medical therapy for 14 days improved
renal function in 10/14 patients with mean serum
creatinine significantly decreasing from 233 mmol/l
to 112 mmol/l. Five responders were then treated
with TIPS and showed further improvement in
renal function (mean glomerular filtration rate:
96620 ml/min at 12 months). Testino et al38
reported the effects of TIPS in 18 patients with
type 2 HRS and a ChildePugh score of 10e12
awaiting transplantation. All patients improved
with respect to ascites and renal function.
These beneficial effects of TIPS on renal function
are difficult to reconcile with the findings by
Malinchoc et al99 who observed a (negative) corre-
lation between the creatinine concentration before
TIPS and survival after TIPS, a fact which was well
recognised in the MELD scoring system. Accord-
ingly, an elevated creatinine concentration should
be a negative predictive factor for the survival after
TIPS. However, numerous studies24 58 including the
meta-analysis by Salerno,50 failed to show a corre-
lation between the pre-TIPS creatinine concentra-
tion and post-TIPS survival. The positive effect of
TIPS on renal function explains that the MELD
score underestimates survival following TIPS for
refractory ascites.100
In summary, TIPS can improve renal function in
type 1 and 2 HRS and eliminate ascites. However,
the data are limited and survival may not be
improved in patients with poor liver function.
Thus, TIPS is indicated in selected patients with
HRS and/or in candidates for liver transplantation.
TREATMENT OF HEPATIC HYDROTHORAX
Hepatic hydrothorax occurs in approximately 5%
of patients with advanced cirrhosis. It is defined as
the presence of pleural fluid (usually greater than
500 ml) without the presence of primary cardiac or
pulmonary disease.5 It is mostly right-sided (85%),
combined with ascites, and due to direct passage of
peritoneal fluid via diaphragmatic leaks. The treat-
ment modalities for hepatic hydrothorax consist of
medical therapy, repeated pleuracenteses, pleurod-
esis, permanent chest tube, surgical repair of the
diaphragmatic leak, peritoneo-venous shunts, and
TIPS.5 101
TIPS for hepatic hydrothorax has been investi-
gated in seven non-controlled studies102e108 and
several case reports. The results of studies including
at least 10 patients are summarised in table 6.
Overall, 198 patients (predominantly ChildePugh
B and C) were included. The mean complete and
partial (not requiring thoracenteses) response rates
were 65% and 15%, respectively. Thus, an overall
clinically relevant response was found in about 70%
of patients. The average 30-day mortality rate was
around 20%. The 1-year survival, given in two
studies,105 108 was 64% and 48%, respectively.
Survival was correlated with response, age
<60e65 years, and the MELD score.
These studies are uncontrolled and most of them
are retrospective. Since patients with refractory
hydrothorax are relatively rare, a randomised
comparison with other treatment options may not
be feasible. Repeated thoracenteses are probably
not an acceptable alternative if required
frequently.109 Pleurodesis is rarely helpful due to
rapid re-accumulation of the pleural effusion and to
side effects. Results of pleurodesis may be improved
by the addition of continuous positive airway
pressure which may keep the pleural space dry.110
However, data are limited to case reports.
According to a recent report using a permanent
chest tube in 17 patients with hepatic hydrothorax,
this treatment should be disregarded.111 Sixteen of
the 17 patients had severe complications including
acute kidney injury (11 patients), pneumothorax
(seven patients) and empyema (five patients). Six
patients (35%) died within 3 months while six of
seven patients who received a TIPS for hepatic
hydrothorax survived. Finally, the video-assisted
thoracoscopy (VATS) for repair of the diaphrag-
matic leak with or without additional pleurodesis
may be an alternative to the TIPS treatment.
However, the overall success rate was only 48% and
mortality was 40% within 40 days of follow-up.112
In summary, compared with other treatment
options, TIPS seems to provide a high rate of
response and rather good long-term survival. In
Table 5 Transplant-free 1- and 2-year survival probabilities and estimated 12-month
mortality according to various MELD scores after TIPS or paracentesis treatment
TIPS (%) Paracentesis (%) HR (p)
1-year survival 63 52.5
2-year survival 49 35.2
12-month mortality
MELD <10 28 42 0.59 (0.18)
MELD 11e19 44 68 0.59 (0.041)
MELD >19 62 84 0.36 (0.13)
Data are derived from the meta-analysis of individual patient data.50 The difference in transplant-free survival was
significant (p<0.05).
HR, hazard ratio; MELD, model of end stage liver disease; TIPS, transjugular intrahepatic portosystemic shunt.
Table 4 Meta-analyses comparing transjugular intrahepatic portosystemic shunt (TIPS) with paracentesis
Author, year (Ref) 24-month survival CI Heterogeneity POR (p value)
Deltenre, 200591 50 vs 42.8% 10 to 23.6 n.g.
Albillos, 200592 0.93 (RR) 0.67 to 1.28 (0.09)
D’Amico 200588 0.90 (POR)0.74* 0.44 to 1.82 0.40 to 1.37* 9.2 (0.056) 5.27 (0.15)*
Saab, 200693 1.26 (POR) 0.65 to 2.56 7.75 (0.1)
Results vary in spite of identical data source. After elimination of heterogeneity survival between groups was significantly different.88
*excluding the French study29.
n.g., not given; POR: pooled odds ratio; RR, relative risk.
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addition, TIPS is the only treatment option which
also treats the refractory ascites, the source of the
hepatic hydrothorax.
CONCLUSIONS
TIPS seems to be the treatment of choice for
patients with ascites requiring repeated and
frequent paracenteses. To reduce shunt-related
complications such as deterioration of liver func-
tion and hepatic encephalopathy, patients should
be selected according to hepatic function (bilirubin
<3 mg/dl). In patients not fulfilling these criteria
TIPS may be justified when it is considered vital
because of the severity of the symptoms or when
liver transplantation is scheduled.
TIPS may also be the treatment of choice in
patients with refractory ascites accompanied by
HRS type 2. As demonstrated in numerous studies,
normalisation of renal function can often be
achieved. In accordance with the guidelines of the
International Ascites Club,4 TIPS can not be
recommended for patients with HRS type 1 due to
lack of sufficient data. In many patients with type
1 HRS TIPS is contraindicated because of the
concurrence of severe hepatic failure. However,
TIPS may be used after vasoconstrictor therapy to
stabilise renal function and possibly improve the
outcome of liver transplantation.
Numerous studies unanimously recommend
TIPS for the treatment of hepatic hydrothorax.
However, due to the lack of comparative trials the
recommendations are of minor evidence suggesting
that treatment should better be based on individual
needs and local facilities.
Most patients with refractory ascites, HRS or
hydrothorax have advanced liver disease with
a higher risk of TIPS-induced complications.
Therefore, the diameter of the stent-shunt which
determines the reduction of the portosystemic
pressure gradient, should be chosen carefully. The
same is true for the type of stent which may be
uncovered in patients at higher risk and covered in
those with a lower risk of shunt-related complica-
tions. A stepwise enlargement of the stent diameter
may help to prevent complications. Liver trans-
plantation should be discussed for patients with
severe complications of cirrhosis such as massive
ascites, HRS or hepatic hydrothorax. The place of
TIPS in the treatment of refractory ascites and its
limitations are summarised in box 2.
Competing interests None.
Provenance and peer review Commissioned; externally peer
reviewed.
REFERENCES
1. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic
criteria of refractory ascites and hepatorenal syndrome in cirrhosis.
International Ascites Club. Hepatology 1996;23:164e76.
2. Moore KP, Aithal GP. Guidelines on the management of ascites
in cirrhosis. Gut 2006;55(Suppl 6):1e12.
3. Gerbes Al. The patient with refractory ascites. Best Pract Res
Clin Gastroent 2007;21:551e60.
4. Salerno F, Gerbes AL, Gine`s P, et al. Diagnosis, prevention, and
treatment of hepatorenal syndrome in cirrhosis. Gut
2007;56;1310e18.
5. Kiafar C, Gilani N. Hepatic hydrothorax: current concepts of
pathophysiology and treatment options. Ann Hepatol
2008;7:313e20.
6. Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis
and diuretics in the treatment of cirrhotics with tense ascites:
results of a randomised study. Gastroenterology
1987;93:234e41.
7. Grabau CM, Crago SF, Hoff LK, et al. Performance standards for
therapeutic abdominal paracentesis. Hepatology
2004;40:484e8.
8. Ro¨ssle M, Richter GM, No¨ldge G, et al. New non-operative
treatment for variceal haemorrhage. Lancet 1989;2:153.
9. Richter GM, Palmaz JC, No¨ldge G, et al. Der transjugulare
intrahepatische portosystemische Stent-Shunt (TIPSS).
Eine neue nichtoperative, perkutane Methode. Radiologe
1989:29:406e11.
10. http://www.TIPS-Register.de.
11. Gatta A, Bolognesi M, Merkel C. Vasoactive factors and
hemodynamic mechanisms in the pathophysiology of
portal hypertension in cirrhosis. Mol Aspects Med
2008;29:119e29.
12. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arteriolar
vasodilation hypothesis: A proposal for the initiation of renal
sodium and water retention in cirrhosis. Hepatology
1988;8:1151e7.
13. Groszmann RJ, Atterbury CE. The pathophysiology of portal
hypertension: a basis for classification. Semin Liver Dis
1982;2:177e86.
Box 2
< TIPS improves survival in well selected patients
with ascites requiring repeated and frequent
paracenteses.
< Patients with a bilirubin concentration <3 mg/
dl, an age <65 years and no history of hepatic
encephalopathy benefit most from TIPS.
< TIPS may be useful as a bridge to trans-
plantation in selected patients with HRS.
< Several uncontrolled studies recommend TIPS
for the treatment of hepatic hydrothorax.
Table 6 Transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of hepatic hydrothorax
Author, year (ref) n Response (%) 30-day mortality (%) 1-year probability of survival (%)
Gordon 1997103 24 79 21*
Jeffries 1998104 12 58 25
Siegerstetter 2001105 40 82 5 64
Spencer 2002106 21 74 29
Wilputte 2007107 28 68 14
Dhanasekaran 2009108 73 75 19 48
Total/range 198 58e82 5e25 48e64
Response rates (complete and partial) and survival data of studies including more than 10 patients.
*45-day mortality.
Gut 2010;59:988e1000. doi:10.1136/gut.2009.193227 997
Recent advances in clinical practice
 group.bmj.com on January 17, 2014 - Published by gut.bmj.comDownloaded from 
14. Møller S, Henriksen JH, Bendtsen F. Ascites: pathogenesis and
therapeutic principles. Scand J Gastroenterol 2009;44:902e11.
15. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of
chronic liver diseases: from the patient to the molecule.
Hepatology 2006;43:S121e31.
16. Korthuis RJ, Kinden DA, Brimer GE, et al. Intestinal capillary
filtration in acute and chronic portal hypertension. Am J Physiol
1988;254:G339e45.
17. Peltekian KM, Wong F, Liu PP, et al. Cardiovascular, renal, and
neurohumoral responses to single large-volume paracentesis in
cirrhotic patients with diuretic-resistant ascites. Am J
Gastroenterol 1997;92:394e9.
18. Runyon BA. Patient selection is important in studying the impact
of large-volume paracentesis on intravascular volume. Am J
Gastroenterol 1997;92:371e3.
19. Cabrera J, Falcon L, Gorriz E, et al. Abdominal decompression
plays a major role in early postparacentesis haemodynamic
changes in cirrhotic patients with tense ascites. Gut
2001;48:384e9.
20. Pozzi M, Ratti L, Redaelli E, et al. Cardiovascular abnormalities in
special conditions of advanced cirrhosis. The circulatory
adaptative changes to specific therapeutic procedures for the
management of refractory ascites. Gastroenterol Hepatol
2006;29:263e72.
21. Gine P, Tito L, Arroyo V, et al. Randomized comparative study of
therapeutic paracentesis with and without intravenous albumin in
cirrhosis. Gastroenterology 1988;94:1493e502.
22. Sola-Vera J, Minana J, Ricart E, et al. Randomized trial
comparing albumin and saline in the prevention of paracentesis-
induced circulatory dysfunction in cirrhotic patients with ascites.
Hepatology 2003;37:1147e53.
23. Martinet JP, Fenyves D, Legault L, et al. Treatment of refractory
ascites using transjugular intrahepatic portosystemic shunt
(TIPS): a caution. Dig Dis Sci 1997;42:161e6.
24. Ochs A, Ro¨ssle M, Haag K, et al. The transjugular intrahepatic
portosystemic stent-shunt procedure for refractory ascites.
N Engl J Med 1995;332:1192e7.
25. Quiroga J, Sangro B, Nunez M, et al. Transjugular intrahepatic
portal-systemic shunt in the treatment of refractory ascites:
effect on clinical, renal, humoral, and hemodynamic parameters.
Hepatology 1995;21:986e94.
26. Somberg KA, Lake JR, Tomlanowich SJ, et al. Transjugular
intrahepatic portosystemic shunts for refractory ascites:
assessment of clinical and hormonal response and renal function.
Hepatology 1995;21:709e16.
27. Spahr L, Fenyves D, N’Guyen VV, et al. Improvement of
hepatorenal syndrome by transjugular intrahepatic portosystemic
shunt. Am J Gastroenterol 1995;90:1169e71.
28. Wong F, Sniderman K, Liu P, et al. Transjugular intrahepatic
portosystemic stent shunt: effects on hemodynamics and sodium
homeostasis in cirrhosis and refractory ascites. Ann Intern Med
1995;122:816e22.
29. Lebrec D, Giuily N, Hadengue A, et al. Transjugular intrahepatic
portosystemic shunts: comparison with paracentesis in patients
with cirrhosis and refractory ascites: a randomized trial. J Hepatol
1996;25:135e44.
30. Jalan R, Redhead DN, Thomas HW, et al. Mechanisms of
changes in renal handling of sodium following transjugular
intrahepatic portosystemic stent-shunt (TIPSS). Eur J
Gastroenterol Hepatol 1996;8:1111e16.
31. Jalan R, Forrest EH, Redhead DN, et al. Reduction in renal blood
flow following acute increase in the portal pressure: evidence
for the existence of a hepatorenal reflex in man. Gut
1997;40:664e70.
32. Wong F, Sniderman K, Liu P, et al. The mechanism of the initial
natriuresis after transjugular intrahepatic portosystemic shunt.
Gastroenterology 1997;112:899e907.
33. Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic
portosystemic shunt in hepatorenal syndrome: effects on renal
function and vasoactive systems. Hepatology 1998;28:416e22.
34. Gerbes AL, Gu¨lberg V, Waggershauser T, et al. Renal effects of
transjugular intrahepatic portosystemic shunt in cirrhosis:
comparison of patients with ascites, with refractory ascites, or
without ascites. Hepatology 1998;28:683e8.
35. Michl P, Gu¨lberg V, Bilzer M, et al. Transjugular intrahepatic
portosystemic shunt for cirrhosis and ascites: effects in patients
with organic or functional renal failure. Scand J Gastroenterol
2000;35:654e8.
36. Brensing KA, Textor J, Perz J, et al. Long term outcome after
transjugular intrahepatic portosystemic stent-shunt in non-
transplant cirrhotics with hepatorenal syndrome: a phase II study.
Gut 2000;47:288e95.
37. Wong W, Liu P, Blendis L, et al. Long-term renal sodium handling
in patients with cirrhosis treated with transjugular intrahepatic
portosystemic shunts for refractory ascites. Am J Med
1999;106:315e22.
38. Testino G, Ferro C, Sumberaz A, et al. Type-2 hepatorenal
syndrome and refractory ascites: role of transjugular intrahepatic
portosystemic stent-shunt in eighteen patients with advanced
cirrhosis awaiting orthotopic liver transplantation. Hepato-
Gastroenterology 2003;50:1753e5.
39. Huonker M, Schumacher YO, Ochs A, et al. Cardiac function and
haemodynamics in alcoholic cirrhosis and effects of the
transjugular intrahepatic portosystemic stent shunt. Gut
1999;44:743e8.
40. Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic
portosystemic shunt: short-term and long-term effects on hepatic
and systemic hemodynamics in patients with cirrhosis.
Hepatology 1999;29:632e9.
41. Azoulay D, Castaing D, Dennison A, et al. Transjugular
intrahepatic portosystemic shunt worsens the hyperdynamic
circulatory state of the cirrhotic patient: preliminary report of
a prospective study. Hepatology 1994;19:129e32.
42. Rodriguez-Laiz JM, Banares R, Echenagusia A, et al. Effects of
transjugular intrahepatic portosystemic shunt (TIPS) on
splanchnic and systemic hemodynamics, and hepatic function in
patients with portal hypertension. Dig Dis Sci 1995;40:2121e7.
43. Colombato LA, Spahr L, Martinet JP, et al. Haemodynamic
adaptation two months after transjugular intrahepatic
portosystemic shunt [TIPS] in cirrhotic patients. Gut
1996;39:600e4.
44. Van der Linden P, Le Moine O, Ghysels M, et al. Pulmonary
hypertension after transjugular intrahepatic portosystemic shunt:
effects on right ventricular function. Hepatology 1996;23:982e7.
45. Stanley AJ, Redhead DN, Bouchier IAD, et al. Acute effects of
the transjugular intrahepatic portosystemic stent-shunt (TIPSS)
on renal blood flow and cardiopulmonary hemodynamics in
cirrhosis. Am J Gastroenterol 1998;93:2463e8.
46. Stadlbauer VP, Wright GAK, Banaji M, et al. Relationship
between activation of the sympathetic nervous system and renal
blood flow autoregulation in cirrhosis. Gastroenterology
2008;134:111e19.
47. Koyama S, Kanai K, Aibiki M, et al. Reflex increase in renal nerve
activity during acutely altered portal venous pressure. J Auton
Nerv Syst 1988;23:55e62.
48. Gu¨lberg V, Haag K, Ro¨ssle M, et al. Hepatic arterial buffer
response in patients with advanced cirrhosis. Hepatology
2002;35:630e4.
49. Radeleff B, Sommer CM, Heye T, et al. Acute increase in
hepatic arterial flow during TIPS identified by intravascular flow
measurements. Cardiovasc Intervent Radiol 2009;32:32e7.
50. Salerno F, Camma C, Enea A, et al. Transjugular intrahepatic
portosystemic shunt for refractory ascites: a meta-analysis of
individual patent data. Gastroenterology 2007;133:825e34.
51. Gu¨lberg V, Liß I, Bilzer M, et al. Improved quality of life in
patients with refractory or recidivant ascites after insertion of
transjugular intrahepatic portosystemic shunts. Digestion
2002;66:127e30.
52. Sanyal AJ, Genning C, Reddy KR, et al. The North American
Study for the treatment of refractory ascites. Gastroenterology
2003;124:634e41.
53. Peng S, Plank LD, McCall JL, et al. Body composition, muscle
function, and energy expenditure in patients with liver cirrhosis:
a comprehensive study. Am J Clin Nutr 2007;85:1257e66.
54. Selberg O, Selberg D. Norms and correlates of bioimpedance
phase angle in healthy human subjects, hospitalized patients, and
patients with liver cirrhosis. Eur J Appl Physiol 2002;86:509e16.
55. Trotter JF, Suhocki PV, Rockey DC. Transjugular intrahepatic
portosystemic shunt (TIPS) in patients with refractory ascites:
effect on body weight and Child-Pugh score. Am J Gastroenterol
1998;93:1891e4.
56. Plauth M, Schuetz T, Buckendahl DP, et al. Weight gain after
transjugular intrahepatic portosystemic shunt (TIPS) is associated
with improvement in body composition in malnourished patients
with cirrhosis and hypermetabolism. J Hepatol 2004;40:228e33.
57. Allard JP, Chau J, Sandokji K, et al. Effects of ascites resolution
after successful TIPS on nutrition in cirrhotic patients with
refractory ascites. Am J Gastroenterol 2001;96:2442e7.
58. Ro¨ssle M, Ochs A, Gulberg V, et al. A comparison of paracentesis
and transjugular intrahepatic portosystemic shunting in patients
with ascites. N Engl J Med 2000;342:1701e7.
59. Riggio O, Merli M, Pedretti G, et al. Hepatic encephalopathy
after transjugular intrahepatic portosystemic shunt. Incidence and
risk factors. Dig Dis Sci 1996;41:578e84.
998 Gut 2010;59:988e1000. doi:10.1136/gut.2009.193227
Recent advances in clinical practice
 group.bmj.com on January 17, 2014 - Published by gut.bmj.comDownloaded from 
60. Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic
encephalopathy after transjugular intrahepatic portosystemic
shunt: results of a prospective controlled study. Hepatology
1994;20:46e55.
61. Rossle M, Piotraschke J. Transjugular intrahepatic
portosystemic shunt and hepatic encephalopathy. Dig Dis
1996;14(Suppl 1):12e19.
62. Somberg KA, Riegler JL, LaBerge JM, et al. Hepatic
encephalopathy after transjugular intrahepatic portosystemic
shunts: incidence and risk factors. Am J Gastroenterol
1995;90:549e55.
63. Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural
history, and risk factors of hepatic encephalopathy after
transjugular intrahepatic portosystemic shunt with
polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol
2008;103:2738e46.
64. Patel NH, Sasadeusz KJ, Seshadri R, et al. Increase in hepatic
arterial blood flow after transjugular intrahepatic portosystemic
shunt creation and its potential predictive value of postprocedural
hepatic encephalopathy and mortality. J Vascular Interv Radiol
2001;12:1279e84.
65. Hauenstein KH, Haag K, Ochs A, et al. The reducing stent:
treatment for transjugular intrahepatic portosystemic shunt-
induced refractory hepatic encephalopathy and liver failure.
Radiology 1995;194:175e9.
66. Kerlan RK Jr, LaBerge JM, Baker EL, et al. Successful reversal
of hepatic encephalopathy with intentional occlusion of
transjugular intrahepatic portosystemic shunts. J Vasc Interv
Radiol 1995;6:917e21.
67. Gerbes AL, Waggershauser T, Holl J, et al. Experiences with
novel techniques for reduction of stent flow in transjugukar
intrahepatic portosystemic shunts. Z Gastroenterol
1998;36:373e7.
68. Ro¨ssle M, Siegerstetter V, Berger E, et al. Epidemiology and
treatment of debilitating hepatic encephalopathy after implantation
of a transjugular intrahepatic portosystemic shunt. In: Yurdaydin C,
Bozkaya H, eds.Advances in hepatic encephalopathy andmetabolism
in liver disease. Ankara, Turkey: Ancara, Turkish Gastroenterology
Foundation, Ankara University Press, 2000: 411e15.
69. Crippin JS, Schmidt RD, Niblett RL, et al. Effect of a transjugular
intrahepatic portosystemic shunt on liver biochemical profiles.
J Vascular Interv Radiol 1995;6:461e4.
70. Chalasani N, Clark WS, Martin LG, et al. Determinants of
mortality in patients with advanced cirrhosis after transjugular
intrahepatic portosystemic shunting. Gastroenterology
2000;118:138e44.
71. Rajan DK, Haskal ZJ, Clark TW. Serum bilirubin and early mortality
after transjugular intrahepatic portosystemic shunts: results of
a multivariate analysis. J Vasc Interv Radiol 2002;13:155e61.
72. Gerbes AL, Gulberg V. Benefit of TIPS for patients with
refractory ascites: serum bilirubin may make the difference.
Hepatology 2005;41:217.
73. Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after
transjugular intrahepatic portosystemic shunt: correlation with
hemodynamic findings. Gastroenterology 1998;114:1296e303.
74. Ro¨ssle M, Siegerstetter V, Huber M, et al. The first decade of
the transjugular intrahepatic portosystemic shunt (TIPS): state of
the art. Liver 1998;18:73e89.
75. Møller S, Henriksen JH. Cardiovascular complications of
cirrhosis. Gut 2008;57:268e78.
76. Pozzi M, Carugo S, Boari G, et al. Evidence of functional and
structural cardiac abnormalities in cirrhotic patients with and
without ascites. Hepatology 1997;26:1131e7.
77. Cazzaniga M, Salerno F, Pagnozzi G, et al. Diastolic dysfunction
is associated with poor survival in cirrhotic patients with
transjugular intrahepatic portosystemic shunt. Gut
2007;56:869e75.
78. Siegerstetter V, Huber M, Ochs A, et al. Platelet aggregation
and platelet-derived growth factor inhibition for prevention of
insufficiency of the transjugular intrahepatic portosystemic shunt:
a randomized study comparing trapidil plus ticlopidine with
heparin treatment. Hepatology 1999;29:33e8.
79. Ro¨ssle M, Siegerstetter V, Euringer W, et al. The use of
a polytetrafluoroethylene-covered stent graft for transjugular
intrahepatic portosystemic shunt (TIPS): long-term follow-up of
100 patients. Acta Radiol 2006;47:660e6.
80. Jung HS, Kalva SP, Greenfield AJ, et al. TIPS: comparison of
shunt patency and clinical outcomes between bare stents and
expanded polytetrafluoroethylene stent-grafts. J Vasc Interven
Radiol 2009;20:180e5.
81. Ro¨ssle M, Siegerstetter V, Olschewski M, et al. How much
reduction in portal pressure is necessary to prevent variceal
rebleeding? A longitudinal study in 225 patients with
a transjugular intrahepatic portosystemic shunt. Am J
Gastroenterol 2001;96:3379e83.
82. Thalheimer U, Leandro G, Samonakis DN, et al. TIPS for
refractory ascites: a single centre experience. J Gastroenterol
2009;44:1089e95.
83. Bureau C, Pagan JC, Layrargues GP, et al. Patency of stents
covered with polytetrafluoroethylene in patients treated by
transjugular intrahepatic portosystemic shunts: long-term results
of a randomized multicentre study. Liver Int 2007;27:742e7.
84. Michl P, Bilzer M, Waggershauser T, et al. Successful treatment
of chronic Budd-Chiari syndrome with a transjugular intrahepatic
portosystemic shunt. J Hepatol 2000;32:516e20.
85. Darwish Murad S, Luong TK, Pattynama PMT, et al. Long-term
outcome of a covered vs. uncovered transjugular intrahepatic
portosystemic shunt in Budd-Chiari syndrome. Liver Int
2008;28:249e56.
86. Gine`s P, Uriz J, Calahorra B, et al. Transjugular intrahepatic
portosystemic shunting versus paracentesis plus albumin for
refractory ascites in cirrhosis. Gastroenterology
2002;123:1839e47.
87. Salerno F, Merli M, Riggio O, et al. Randomized controlled study
of TIPS versus paracentesis plus albumin in cirrhosis with severe
ascites. Hepatology 2004;40:629e35.
88. D’Amico G, Luca A, Morabito A, et al. Uncovered transjugular
intrahepatic portosystemic shunt for refractory ascites: a meta-
analysis. Gastroenterology 2005;129:1282e93.
89. Ro¨ssle M. Discussion of the North American study for the
treatment of refractory ascites. Gastroenterology
2004;126:1214e15.
90. Ro¨ssle M, Euringer W. Transjugular intrahepatic portosystemic
shunt versus paracentesis: a critical review of randomized studies
and meta-analyses. FALK Symposium 162. In: Bosch J,
Burroughs AK, Lammert F, et al. eds. Liver cirrhosis: from
pathophysiology to disease management. Dordrecht, NL:
Springer, 2008:261e6.
91. Deltenre P, Mathurin P, Dharancy S, et al. Transjugular
intrahepatic portosystemic shunt in refractory ascites: a meta-
analysis. Liver Int 2005;25:349e56.
92. Albillos A, Banares R, Gonzalez M, et al. A meta-analysis of
transjugular intrahepatic portosystemic shunt versus paracentesis
for refractory ascites. J Hepatol 2005;43:990e6.
93. Saab S, Nieto JM, Ly D, et al. TIPS versus paracentesis for
cirrhotic patients with refractory ascites. Cochrane Database Syst
Rev 2004;(3):CD004889.
94. Russo MW, Sood A, Jacobson IM, et al. Transjugular
intrahepatic portosystemic shunt for refractory ascites: an
analysis of the literature on efficacy, morbidity, and mortality. Am
J Gastroenterol 2003;98:2521e7.
95. Gluud LL, Christensen K, Christensen E, et al. Systematic review
of randomized trials on vasoconstrictor for hepatorenal syndrome.
Hepatology 2010;51:576e84.
96. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function
predicts survival in patients undergoing orthotopic liver
transplantation. Hepatology 2002;35:1179e85.
97. Guerrini GP, Pleguezuelo M, Maimone S, et al. Impact of TIPS
pre liver transplantation for the outcome post transplantation. Am
J Transplant 2009;9:192e200.
98. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin,
and TIPS in selected patients with cirrhosis and type 1
hepatorenal syndrome. Hepatology 2004;40:55e64.
99. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict
poor survival in patients undergoing transjugular intrahepatic
portosystemic shunts. Hepatology 2000;31:864e71.
100. Alessandria C, Gaia S, Marzano A, et al. Application of the
model for end-stage liver disease score for transjugular
intrahepatic portosystemic shunt in cirrhotic patients with
refractory ascites and renal impairment. Eur J Gastroenterol
Hepatol 2004;16:607e12.
101. Cardenas A, Kelleher T, Chopra S. Hepatic hydrothorax. Alimen
Pharmacol Therapeut 2004;20:271e9.
102. Strauss RM,Martin LG, Kaufman SL, et al. Transjugular intrahepatic
portal systemic shunt for the management of symptomatic
cirrhotic hydrothorax. Am J Gastroenterol 1994;92:1520e2.
103. Gordon FD, Anastopoulos HT, Crenshaw W, et al. The
successful treatment of symptomatic, refractory hepatic
hydrothorax with transjugular intrahepatic portosystemic shunt.
Hepatology 1997;25:1366e9.
104. Jeffries MA, Kazanjian S, Wilson M, et al. Transjugular
intrahepatic portosystemic shunts and liver transplantation in
patients with refractory hepatic hydrothorax. Liver Transpl Surg
1998;4:416e23.
Gut 2010;59:988e1000. doi:10.1136/gut.2009.193227 999
Recent advances in clinical practice
 group.bmj.com on January 17, 2014 - Published by gut.bmj.comDownloaded from 
105. Siegerstetter V, Deibert P, Ochs A, et al. Treatment of
refractory hepatic hydrothorax with TIPS: long term results in 40
patients. Eur J Gastroenterol Hepatol 2001;13:529e34.
106. Spencer EB, Cohen DT, Darey MD. Safety and efficacy of
transjugular intrahepatic portosystemic shunt creation for the
treatment of hepatic hydrothorax. J Vasc Interv Radiology
2002;13:385e90.
107. Wilputte JY, Goffette P, Zech F, et al. The outcome after
transjugular intrahepatic portosystemic shunt (TIPS) for
hepatic hydrothorax is closely related to liver dysfunction:
a long-term study in 28 patients. Acta Gastroenterol Belg
2007;70:6e10.
108. Dhanasekaran R, West JK, Gonzales PC, et al. Transjugular
intrahepatic portosystemic shunt for symptomatik refractory
hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol
Published online first. 10 Nov 2009; doi:10.1038/ajg.2009.634.
109. Lazaridis KN, Frank JW, Krowka MJ, et al. Hepatic hydrothorax:
pathogenesis, diagnosis and management. Am J Med
1999;107:262e7.
110. Drouhin F, Fischer D, Law Koune JD, et al. Treatment of
hydrothorax in liver cirrhosiswith chemical pleurodesis associated
with continuous positive airway pressure ventilation.
Gastroenterol Clin Biol 1991;15:271e2.
111. Orman ES, Lok AS. Outcomes of patients with chest tube
insertion for hepatic hydrothorax. Hepatol Int 2009;3:582e6.
112. Milanez de Campos Jr, Filho LO, de Campos WE, et al.
Thoracoscopy and talc poudrage in the management of hepatic
hydrothorax. Chest 2000;118:13e17.
1000 Gut 2010;59:988e1000. doi:10.1136/gut.2009.193227
Recent advances in clinical practice
 group.bmj.com on January 17, 2014 - Published by gut.bmj.comDownloaded from 
doi: 10.1136/gut.2009.193227
 2010 59: 988-1000Gut
 
Martin Rössle and Alexander L Gerbes
 
hydrothorax: a critical update
hepatorenal syndrome and hepatic 
TIPS for the treatment of refractory ascites,
 http://gut.bmj.com/content/59/7/988.full.html
Updated information and services can be found at: 
These include:
References
 http://gut.bmj.com/content/59/7/988.full.html#related-urls
Article cited in: 
 
 http://gut.bmj.com/content/59/7/988.full.html#ref-list-1
This article cites 107 articles, 10 of which can be accessed free at:
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Collections
Topic
 (65 articles)GUT Recent advances in clinical practice   
 (79 articles)Editor's choice   
 
Articles on similar topics can be found in the following collections
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on January 17, 2014 - Published by gut.bmj.comDownloaded from 
